PDF(Pubmed)
Abstract：
The management of elderly patients diagnosed with acute myelogenous leukemia (AML) is complicated by high relapse risk and comorbidities that often preclude access to allogeneic hematopoietic cellular transplantation (allo-HCT). In recent years, fast-paced FDA drug approval has reshaped the therapeutic landscape, with modest, albeit promising improvement in survival. Still, AML outcomes in elderly patients remain unacceptably unfavorable highlighting the need for better understanding of disease biology and tailored strategies. In this review, we discuss recent modifications suggested by European Leukemia Network 2022 (ELN-2022) risk stratification and review recent aging cell biology advances with the discussion of four AML cases. While an older age, >60 years, does not constitute an absolute contraindication for allo-HCT, the careful patient selection based on a detailed and multidisciplinary risk stratification cannot be overemphasized.
摘要：
诊断为急性骨髓性白血病（AML）的老年患者的治疗因复发风险高和合并症而变得复杂，这些合并症通常无法获得异基因造血细胞移植（allo-HCT）。近年来,快节奏的FDA药物批准重塑了治疗领域，谦虚,尽管在生存方面有希望改善。尽管如此，老年患者的AML结局仍然令人无法接受，这表明需要更好地了解疾病生物学和定制策略。在这次审查中,我们讨论了欧洲白血病网络2022(ELN-2022)风险分层建议的最新修改,并通过对4例AML病例的讨论回顾了近期衰老细胞生物学进展.虽然年龄较大，>60年,不构成allo-HCT的绝对禁忌症，基于详细和多学科的风险分层的精心选择患者怎么强调都不为过.
